This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): Thrombin stand-alone
Description: Evithrom is derived from human plasma and is designed to provide effective hemostasis without the risk of adverse reactions associated with the use of bovine sourced hemostats. Thrombin is a protease (an enzyme that cleaves proteins) which plays a critical role in hemostasis (the stopping of bleeding). It converts fibrinogen into an active form and also activates factors XI, V, and VIII of the coagulation cascade. Thrombin also acts on receptors to activate platelets and produce pro-inflammatory and pro-fibrotic effects.
Deal Structure: In September 2003, OMRIX entered into a development, distribution and supply agreement with Ethicon Inc., a Johnson and Johnson company. OMRIX will manufacture products and hold regulatory licenses; Ethicon will retain exclusive sales and marketing rights in the U.S. and EU to OMRIX biosurgical products (in the areas of hemostasis and sealing only). Together, OMRIX and Ethicon will co-develop thrombin stand-alone. Under the terms of the agreement, Ethicon will pay most development costs and OMRIX will receive a percentage of all revenues gained from the sales of the products.
In November 2008, Johnson & Johnson and Omrix Biopharmaceuticals announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer. Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc.
In December 2008, Johnson & Johnson completed its acquisition of Omrix Biopharmaceuticals.
Additional information available to subscribers only: